Fairvalue-Calculator Fairvalue-Calculator
EN DE

Newland Pharmaceutical Co (301277) Fair Value & Analysis

Healthcare · CN · Market cap 3.6B CNY

Price¥9.03
Fair Value¥4.48
Upside-50.4%
Quality95/100
Evidence: High Range ¥3.35 – ¥6.77

Fair value as of: Jun 24, 2026

Analysis

Newland Pharmaceutical Co (301277) currently trades at ¥9.03, while our model-based Fair Value estimate is ¥4.48 — implying the stock looks roughly 50.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Newland Pharmaceutical Co (301277) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥4.48 versus a price of ¥9.03 — about −50% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 301277?
Our 21-model fair value for Newland Pharmaceutical Co is ¥4.48 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥9.03.
What is the quality score of 301277?
Newland Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.